An interventional study of The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Mississippi Aphasia Screening Test in Mild Cognitive Impairment (MCI), Dementia and Mild Cognitive Impairment (MCI) Amnestic, sponsored by Faculty Hospital Kralovske Vinohrady. Enrolling by invitation at 3 sites in Czechia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Faculty Hospital Kralovske Vinohrady · Not applicable, Interventional, and Diagnostic
Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
This study's planned enrollment of 500 is above the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Faculty Hospital Kralovske Vinohrady is the lead sponsor of 30 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for the group of healthy participants:
Inclusion Criteria for the group of patients:
- be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The experimental group consists of patients with Mild Cognitive Impariment (MCI) and dementia.
Diagnostic Test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) · Diagnostic Test: the Mississippi Aphasia Screening Test · Diagnostic Test: Amnesia Light and Brief Assessment (ALBA) · Diagnostic Test: The Picture naming and immediate recall test (PICNIR) · Diagnostic Test: Geriatric Depression Scale (GDS-15) · Diagnostic Test: The Beck Anxiety Inventory (BAI) · Diagnostic Test: Digitial Diagnostics of Dementia (DDD)
The control group consists of cognitively healthy elderly participants.
Diagnostic Test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) · Diagnostic Test: the Mississippi Aphasia Screening Test · Diagnostic Test: Amnesia Light and Brief Assessment (ALBA) · Diagnostic Test: The Picture naming and immediate recall test (PICNIR) · Diagnostic Test: Geriatric Depression Scale (GDS-15) · Diagnostic Test: The Beck Anxiety Inventory (BAI) · Diagnostic Test: Digitial Diagnostics of Dementia (DDD)
A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.
he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).
The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.
A formative assessment and rating scale of anxiety.
Our experimental screening battery developed for this study.
The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)
Time frame: Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with RBANS
Time frame: Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with MAST
Time frame: Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with ALBA
Time frame: Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with POBAV
Time frame: Through study completion, an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Faculty Hospital Kralovske Vinohrady